Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.66 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.66 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 8/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022394 | 0.93 | LMNA (0.65) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL6022385 | 0.92 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6023266 | 0.91 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL6023256 | 0.90 | LMNA (0.61) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL236108 | 0.89 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6060610 | 0.89 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL11852751 | 0.88 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL331768 | 0.88 | LMNA (0.70) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL30608768 | 0.88 | LMNA (0.74) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10612107 | 0.86 | LMNA (0.65) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232185-A | Preparation process of monatibavir | 迪维实验室有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-119708098-A | Antiviral and antibacterial N4-hydroxycytidine derivative, application and preparation method thereof | 中国人民解放军军事科学院军事医学研究院 | 2025-03-28 | — | — | CN | disclosed |
| CN-115232185-A | Preparation process of monatibavir | 迪维实验室有限公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2022168107-A1 | ENZYMATIC SYNTHESIS OF MOLNUPIRAVIR INTERMEDIATE | FERMENTA BIOTECH LIMITED (IN) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022168106-A1 | CHEMO-ENZYMATIC PROCESS FOR SYNTHESIS OF MOLNUPIRAVIR | FERMENTA BIOTECH LIMITED (IN) | 2022-08-11 | — | — | WO | disclosed |
| US-11407779-B1 | Process for the preparation of molnupiravir | DIVI'S LABORATORIES LTD. (IN) | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407779-B1 | Process for the preparation of molnupiravir | ALKBH1, ALKBH5, ALKBH3 | LMNA 2502/4885THRB 558/4885MTOR 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.